肺大细胞神经内分泌癌临床分子诊断和治疗研究进展  

Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma

作　　者：韩艺 张同梅[2,3] 齐菲 张泳 Han Yi;Zhang Tongmei;Qi Fei;Zhang Yong(First School of Clinical Medicine of Shaanxi University of Chinese Medicine,Xianyang 712046,China;Department of General,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China;Laboratory for Clinical Medicine,Capital Medical University,Beijing 101149,China;Department of Cardiothoracic Surgery,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China)

机构地区：[1]陕西中医药大学第一临床医学院,咸阳712046 [2]首都医科大学附属北京胸科医院综合科,北京101149 [3]首都医科大学基础临床联合实验室,北京101149 [4]陕西中医药大学附属医院胸心外科,咸阳712000

出　　处：《国际肿瘤学杂志》2024年第7期468-473,共6页Journal of International Oncology

基　　金：北京市属医学科研院所公益发展改革试点项目(JYY2023-14、JYY2023-15)。

摘　　要：肺大细胞神经内分泌癌(LCNEC)是一类少见的恶性神经内分泌肿瘤,总体预后不佳,晚期患者中位总生存期仅1年左右。随着分子诊断、靶向治疗和免疫治疗的应用,非小细胞肺癌患者预后显著改善,然而LCNEC诊疗的进展相对缓慢,目前尚无统一标准的诊断、治疗方案。LCNEC临床分子诊断和治疗研究具有重要意义,探讨LCNEC诊断、治疗相关研究进展,可为改善LCNEC现存临床诊断、治疗困境提供参考。Pulmonary large cell neuroendocrine carcinoma(LCNEC)is a rare type of malignant neuroendocrine tumor with poor prognosis,with the median overall survival being around one year in advanced diseases.The prognosis of patients with non-small cell lung cancer has been greatly improved with the application of molecular detecting techniques,targeted therapy and immunotherapy.However,little progress has been made in the diagnosis and treatment of LCNEC with no unified standard of diagnosis and treatment protocol.The clinical molecular diagnosis and treatment of LCNEC is of great significance.Exploring the research progress related to the diagnosis and treatment of LCNEC can provide reference for improving the existing clinical diagnosis and treatment difficulties of LCNEC.

关 键 词：肺肿瘤 癌 神经内分泌 病理学 分子 肿瘤治疗方案 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]